^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CMTM6 overexpression

    i
    Other names: CMTM6, CKLF Like MARVEL Transmembrane Domain Containing 6, CKLF-Like MARVEL Transmembrane Domain-Containing Protein 6, Chemokine-Like Factor Superfamily Member 6, Chemokine-Like Factor Super Family 6, Chemokine-Like Factor Superfamily 6, CKLFSF6, CKLF-Like MARVEL Transmembrane Domain Containing 6, FLJ20396, PRO2219
    Entrez ID:
    54918
    Related biomarkers:
    Expression
    1year
    CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma. (PubMed, Funct Integr Genomics)
    CMTM6 overexpression shapes the inflammatory TME with a strong immune response. These findings support that CMTM6 is an immunotherapeutic target with promising effect to treat PAAD.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    CMTM6 overexpression
    almost2years
    CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. (PubMed, Mol Cancer)
    Co-immunoprecipitation revealed that CMTM6 directly interacted with HER2 in HER2+ breast cancer cells, and CMTM6 overexpression inhibited HER2 ubiquitination. Collectively, these findings highlight that CMTM6 stabilizes HER2 protein, contributing to trastuzumab resistance and implicate CMTM6 as a potential prognostic marker and therapeutic target for overcoming trastuzumab resistance in HER2+ breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    HER-2 positive • HER-2 overexpression • HER-2 expression • EGFR positive • CMTM6 overexpression
    |
    Herceptin (trastuzumab)
    2years
    CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis. (PubMed, FASEB J)
    Overall, our study suggests that CMTM6 is a major regulator of the ribosome biogenesis network and targeting the ribosome biogenesis network is a viable target to overcome chemoresistance in OSCC. The novel combination of CX-5461 and cisplatin deserves further clinical investigation in advanced OSCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    MYC expression • CMTM6 overexpression
    |
    cisplatin • pidnarulex (CX-5461)
    almost3years
    Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer. (PubMed, Front Mol Biosci)
    Last, copy number variations (CNVs) and DNA methylation might prompt the abnormal CMTM6 expression in OV. In conclusion, CMTM6 can serve as a novel prognostic biomarker in patients with OV.
    Journal
    |
    CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    CMTM6 overexpression
    over3years
    CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells. (PubMed, J Transl Med)
    CMTM6 has an important function in HCC proliferation, migration, and invasion, via its interaction with and stabilization of vimentin. CMTM6 might represent a potential biomarker and therapeutic target to treat HCC.
    Journal
    |
    VIM (Vimentin) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    VIM expression • CMTM6 overexpression